# Roivant Sciences Shares Phase 3 Uveitis Drug Results

> Roivant Sciences reveals Phase 3 results for brepocitinib in non-infectious uveitis.
- Title: Roivant Sciences Shares Phase 3 Uveitis Drug Results
- Summary: Roivant Sciences reveals Phase 3 results for brepocitinib in non-infectious uveitis. Roivant Sciences announced Phase 3 results for brepocitinib treating…
- Keywords: roivant sciences, brepocitinib, non-infectious uveitis, phase 3 results, nasdaq:roiv, money, business, Roivant, Sciences, Shares, Phase, Uveitis
- Source: Seekingalpha — https://seekingalpha.com/article/4957274-roivant-sciences-ltd-roiv-discusses-phase-3-results-for-brepocitinib-in-non-infectious
- Author: SA Transcripts
- Published: 2026-10-24T23:16:09+00:00
- Read time: 1 min
- Topics: roivant sciences, brepocitinib, non-infectious uveitis, phase 3 results, nasdaq:roiv, money, business
## Roivant Sciences
Roivant Sciences Ltd. published a slide deck discussing Phase 3 results for brepocitinib in non-infectious uveitis.
## Phase 3 Results
The company shared findings on brepocitinib's effectiveness for non-infectious uveitis treatment.
## Event Details
The slide deck was published by Roivant Sciences in conjunction with this event on NASDAQ:ROIV.
## Key takeaway

Roivant Sciences announced Phase 3 results for brepocitinib treating non-infectious uveitis.